L'Oreal Q3 sales
This article was originally published in The Rose Sheet
Executive Summary
In response to rumors that Avon is on the firm's acquisition radar, CEO Jean-Paul Agon told analysts during a third-quarter sales call that he would not give a direct answer but acknowledged "we have huge opportunities in existing channels." Rumors began circulating last week that the French firm may be interested in the direct seller as a means to increase its exposure in developing markets and enter the direct-selling channel (1"The Rose Sheet" Oct. 18, 2010). In the third quarter, consumer products sales advanced 6.5%, based on comparable structure and exchange rates, to €2.4 billion, due in part to "very strong dynamism" of Maybelline, the firm says. Luxury products were up 5.7% to €1.14 billion, driven by strong sales of Yves Saint Laurent fragrances. Geographically, North America generated sales of €1.13 billion, representing growth of 3.8%, boosted by consumer and luxury products. L'Oreal is seeing its biggest gains in new markets, including Asia Pacific (up 11.5%) and Latin America (up 18.2%). Net sales in the third quarter rose 5.5% to €4.53 billion. To stay abreast of changes in marketing and the digital world, the firm has created a strategic marketing group led by Marc Menesguen, former president of Lancome
You may also be interested in...
M&A Chatter: Analysts Speculate On L'Oreal/Avon, P&G/Beiersdorf Deals
In the wake of Unilever's $3.7 billion acquisition of Alberto Culver, whispers of similar deals have rippled through the personal-care industry, including a possible L'Oreal bid for direct seller Avon
Entries Begin To Roll In For 2024 Industry Awards
Entries have now begun rolling in for the Global Generics & Biosimilars Awards, which returns to Milan this October, Free to enter and attend, the ceremony recognizes the top achievements across the generics, biosimilars and value added medicines industries.
‘I Would Love To Have All The Biologic Assets’ – Formycon’s Glombitza Sets Out Portfolio Approach
In the second part of an exclusive interview, Formycon CEO Stefan Glombitza talks to Generics Bulletin about key regulatory developments in Europe and the US, the firm’s portfolio selection strategy, and upcoming milestones on the horizon.